Literature DB >> 18784314

Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program.

M A Pfaller1, L B Boyken, R J Hollis, J Kroeger, S A Messer, S Tendolkar, D J Diekema.   

Abstract

We performed 24- and 48-h MIC determinations and disk diffusion testing of fluconazole against more than 11,000 clinical isolates of Candida species. By using the reference MIC breakpoints, the categorical agreement between the 24-h and reference 48-h broth microdilution results ranged from 93.8% (all Candida species) to 94.9% (all Candida species minus Candida krusei), with only 0.1% very major errors (VME). The essential agreement (within 2 log(2) dilutions) between the 24-h and 48-h results was 99.6%. The categorical agreement between the 24-h disk diffusion results and the 24-h MIC results, using the previously established breakpoints, was 94.4%, with 0.1% VME. Both the MIC and the disk diffusion results obtained for fluconazole after only 24 h of incubation may be used to determine the susceptibilities of Candida spp. to this widely used antifungal agent.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18784314      PMCID: PMC2576604          DOI: 10.1128/JCM.01391-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  36 in total

1.  Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.

Authors:  Kevin W Garey; Milind Rege; Manjunath P Pai; Dana E Mingo; Katie J Suda; Robin S Turpin; David T Bearden
Journal:  Clin Infect Dis       Date:  2006-05-16       Impact factor: 9.079

Review 2.  Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

Authors:  M A Pfaller; D J Diekema; D J Sheehan
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 3.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

Authors:  J H Rex; M A Pfaller; J N Galgiani; M S Bartlett; A Espinel-Ingroff; M A Ghannoum; M Lancaster; F C Odds; M G Rinaldi; T J Walsh; A L Barry
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

4.  International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; F Barchiesi; M Cuenca-Estrella; M A Pfaller; M Rinaldi; J L Rodriguez-Tudela; P E Verweij
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

5.  Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study.

Authors:  A Espinel-Ingroff; F Barchiesi; M Cuenca-Estrella; A Fothergill; M A Pfaller; M Rinaldi; J L Rodriguez-Tudela; P E Verweij
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

6.  Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy.

Authors:  Shelley S Magill; Christine Shields; Cynthia L Sears; Michael Choti; William G Merz
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

7.  Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method.

Authors:  S G Revankar; W R Kirkpatrick; R K McAtee; A W Fothergill; S W Redding; M G Rinaldi; T F Patterson
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

8.  Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.

Authors:  Matthew Morrell; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 9.  Role of antifungal susceptibility testing in patient management.

Authors:  Graeme Forrest
Journal:  Curr Opin Infect Dis       Date:  2006-12       Impact factor: 4.915

10.  Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms.

Authors:  A Espinel-Ingroff; M Pfaller; S A Messer; C C Knapp; S Killian; H A Norris; M A Ghannoum
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

View more
  17 in total

Review 1.  Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948

2.  Validation of 24-hour flucytosine MIC determination by comparison with 48-hour determination by the Clinical and Laboratory Standards Institute M27-A3 broth microdilution reference method.

Authors:  Shawn R Lockhart; Carol B Bolden; Naureen Iqbal; Randall J Kuykendall
Journal:  J Clin Microbiol       Date:  2011-10-19       Impact factor: 5.948

3.  Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program.

Authors:  M A Pfaller; L B Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2011-02-02       Impact factor: 5.948

4.  Multidrug-resistant endemic clonal strain of Candida auris in India.

Authors:  A Chowdhary; V Anil Kumar; C Sharma; A Prakash; K Agarwal; R Babu; K R Dinesh; S Karim; S K Singh; F Hagen; J F Meis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-12-20       Impact factor: 3.267

5.  Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2010-12-15       Impact factor: 5.948

6.  A detailed lipidomic study of human pathogenic fungi Candida auris.

Authors:  Garima Shahi; Mohit Kumar; Sonam Kumari; Shivaprakash M Rudramurthy; Arunaloke Chakrabarti; Naseem A Gaur; Ashutosh Singh; Rajendra Prasad
Journal:  FEMS Yeast Res       Date:  2020-09-01       Impact factor: 2.796

7.  In vitro investigation of antifungal activity of allicin alone and in combination with azoles against Candida species.

Authors:  Alireza Khodavandi; Fahimeh Alizadeh; Farzad Aala; Zamberi Sekawi; Pei Pei Chong
Journal:  Mycopathologia       Date:  2009-11-19       Impact factor: 2.574

8.  Comparison of 24-hour and 48-hour voriconazole MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) in three laboratories: results obtained with 2,162 clinical isolates of Candida spp. and other yeasts.

Authors:  Ana Espinel-Ingroff; E Canton; J Peman; M G Rinaldi; A W Fothergill
Journal:  J Clin Microbiol       Date:  2009-07-01       Impact factor: 5.948

9.  Reliability of the Vitek 2 yeast susceptibility test for detection of in vitro resistance to fluconazole and voriconazole in clinical isolates of Candida albicans and Candida glabrata.

Authors:  Brunella Posteraro; Rosa Martucci; Marilena La Sorda; Barbara Fiori; Dominique Sanglard; Elena De Carolis; Ada Rita Florio; Giovanni Fadda; Maurizio Sanguinetti
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948

10.  Invasive mycosis due to species of Blastobotrys in immunocompromised patients with reduced susceptibility to antifungals.

Authors:  Anil Kumar; Rachana Babu; Swapna Bijulal; Mohan Abraham; P Sasidharan; Shallu Kathuria; Cheshta Sharma; Jacques F Meis; Anuradha Chowdhary
Journal:  J Clin Microbiol       Date:  2014-08-27       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.